↓ Skip to main content

Can brain impermeable BACE1 inhibitors serve as anti-CAA medicine?

Overview of attention for article published in BMC Neurology, August 2017
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Can brain impermeable BACE1 inhibitors serve as anti-CAA medicine?
Published in
BMC Neurology, August 2017
DOI 10.1186/s12883-017-0942-y
Pubmed ID
Authors

Jian-Ming Li, Li-Ling Huang, Fei Liu, Bei-Sha Tang, Xiao-Xin Yan

Abstract

Cerebral amyloid angiopathy (CAA) is characterized by the deposition of ß-amyloid peptides (Aß) in and surrounding the wall of microvasculature in the central nervous system, together with parenchymal amyloid plaques collectively referred to as cerebral amyloidosis, which occurs in the brain commonly among the elderly and more frequently in patients with Alzheimer's disease (AD). CAA is associated with vascular injury and may cause devastating neurological outcomes. No therapeutic approach is available for this lesion to date. ß-Secretase 1 (BACE1) is the enzyme initiating Aß production. Brain permeable BACE1 inhibitors targeting primarily at the parenchymal plaque pathology are currently evaluated in clinical trials. This article presents findings in support of a role of BACE1 elevation in the development of CAA, in addition to plaque pathogenesis. The rationale, feasibility, benefit and strategic issues for developing BACE1 inhibitors against CAA are discussed. Brain impermeable compounds are considered preferable as they might exhibit sufficient anti-CAA efficacy without causing significant neuronal/synaptic side effects. Early pharmacological intervention to the pathogenesis of CAA is expected to provide significant protection for cerebral vascular health and hence brain health. Brain impermeable BACE1 inhibitors should be optimized and tested as potential anti-CAA therapeutics.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 17%
Student > Bachelor 3 13%
Student > Ph. D. Student 3 13%
Student > Master 3 13%
Professor 2 8%
Other 5 21%
Unknown 4 17%
Readers by discipline Count As %
Neuroscience 5 21%
Medicine and Dentistry 5 21%
Agricultural and Biological Sciences 4 17%
Computer Science 2 8%
Psychology 1 4%
Other 3 13%
Unknown 4 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 August 2017.
All research outputs
#10,342,173
of 11,662,003 outputs
Outputs from BMC Neurology
#1,221
of 1,339 outputs
Outputs of similar age
#221,838
of 262,784 outputs
Outputs of similar age from BMC Neurology
#18
of 21 outputs
Altmetric has tracked 11,662,003 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,339 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,784 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.